The main objectives were, first, to investigate whether CSF SNAP‐25 can differentiate between disease stages in AD and between cognitive decline of different etiologies and, second, to understand the clinical applicability of SNAP‐25 by investigating the association between SNAP‐25 and conventional AD biomarkers. Here, SNAP25 is linked to Alzheimer disease.